{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:46:08Z","timestamp":1772894768261,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Free Radical Biology and Medicine"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.freeradbiomed.2004.11.033","type":"journal-article","created":{"date-parts":[[2004,12,21]],"date-time":"2004-12-21T20:35:48Z","timestamp":1103661348000},"page":"568-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Oxidant stress but not thromboxane decreases with epoprostenol therapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Ivan M.","family":"Robbins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian W.","family":"Christman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib1","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","article-title":"Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol","volume":"167","author":"Kuhn","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0002-9149(98)00439-1","article-title":"Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure","volume":"82","author":"Montalescot","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib5","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0735-1097(99)00320-4","article-title":"The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension","volume":"34","author":"Rich","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib6","first-page":"171","article-title":"Study of the mechanism of prostacyclin (PGI2) action on myocardial contractility","volume":"37","author":"Pavlovic","year":"1992","journal-title":"Agents Actions Suppl."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0022-2828(91)90218-B","article-title":"Prostaglandin I2 (PGI2) enhances calcium current in guinea-pig ventricular heart cells","volume":"23","author":"Alloatti","year":"1991","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJM198809153191106","article-title":"Clinical implications of prostaglandin and thromboxane A2 formation (Part One)","volume":"319","author":"Oates","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib9","first-page":"42","article-title":"Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells","volume":"48","author":"Dorn","year":"1997","journal-title":"Agent Action Suppl."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib10","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1161\/01.CIR.99.25.3266","article-title":"Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension","volume":"99","author":"Langleben","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib11","doi-asserted-by":"crossref","first-page":"9383","DOI":"10.1073\/pnas.87.23.9383","article-title":"A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism","volume":"87","author":"Morrow","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1164\/ajrccm.164.6.2104033","article-title":"Increased lipid peroxidation in patients with pulmonary hypertension","volume":"164","author":"Cracowski","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1164\/rccm.200301-147OC","article-title":"Oxidative Stress in Severe Pulmonary Hypertension","volume":"169","author":"Bowers","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib14","doi-asserted-by":"crossref","first-page":"L1067","DOI":"10.1152\/ajplung.2001.280.6.L1067","article-title":"Isoprostanes: an overview and putative roles in pulmonary pathophysiology","volume":"280","author":"Janssen","year":"2001","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib16","first-page":"R1406","article-title":"A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F2 alpha on retinal vessels","volume":"274","author":"Lahaie","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1523-1755.1999.00596.x","article-title":"Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells","volume":"56","author":"Yura","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension: a national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib19","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199110173251605","article-title":"Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin","volume":"325","author":"Clarke","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0076-6879(99)00106-8","article-title":"Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress","volume":"300","author":"Morrow","year":"1999","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0009-8981(01)00637-4","article-title":"Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-isoprostane (8-iso-PGF(2alpha)) by a stable isotope dilution mass spectrometric assay","volume":"314","author":"Morales","year":"2001","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0378-4347(93)80161-V","article-title":"Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry","volume":"612","author":"Morrow","year":"1993","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.RES.87.10.840","article-title":"Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress","volume":"87","author":"Cai","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-2143(98)90019-1","article-title":"Redox control of vascular smooth muscle proliferation","volume":"132","author":"Griendling","year":"1998","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1006812003834","article-title":"Prostaglandins attenuate cardiac contractile dysfunction produced by free radical generation but not by hydrogen peroxide","volume":"176","author":"Zimmer","year":"1997","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/ajh\/6.6.463","article-title":"Possible radical scavenging properties of cicletanine and renal protection in Dahl salt sensitive rats","volume":"6","author":"Uehara","year":"1993","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-6632.1994.tb36774.x","article-title":"Protective effects of prostaglandin I2 analogues on superoxide-induced hepatocyte injury","volume":"723","author":"Nakano","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib28","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1210\/en.2003-1583","article-title":"Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells","volume":"145","author":"Yoshimoto","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1006\/exer.1997.0370","article-title":"Induction of human thioredoxin in cultured human retinal pigment epithelial cells through cyclic AMP-dependent pathway; involvement in the cytoprotective activity of prostaglandin E1","volume":"65","author":"Yamamoto","year":"1997","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1152\/jappl.1993.74.1.460","article-title":"Airway and vascular effects of 8-epi-prostaglandin F2 alpha in isolated perfused rat lung","volume":"74","author":"Kang","year":"1993","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1378\/chest.120.4.1226","article-title":"Plasma markers of endothelial dysfunction in pulmonary hypertension","volume":"120","author":"Cella","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib33","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1161\/01.RES.88.2.e14","article-title":"Mechanisms underlying endothelial dysfunction in diabetes mellitus","volume":"88","author":"Hink","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib35","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1054-8807(01)00095-3","article-title":"Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells","volume":"10","author":"Ruef","year":"2001","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0049-3848(84)90036-7","article-title":"Inhibition of platelet activation by prostacyclin: possible consequences in coagulation and anticoagulation","volume":"21","author":"Bunting","year":"1981","journal-title":"Thromb. Res."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1055\/s-0038-1650601","article-title":"Inhibitory effect of prostacyclin and nitroprusside on type IIB von Willebrand factor-promoted platelet activation","volume":"76","author":"Francesconi","year":"1996","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.freeradbiomed.2004.11.033_bib39","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1006\/bbrc.1994.2396","article-title":"In vitro antioxidant activity of calcium antagonists against LDL-oxidation compared with alpha-tocopherol","volume":"203","author":"Lupo","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2004.11.033_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1054\/plef.1999.0088","article-title":"Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidation","volume":"61","author":"Kritz","year":"1999","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"}],"container-title":["Free Radical Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891584904009657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891584904009657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:55:53Z","timestamp":1760198153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891584904009657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0891584904009657"],"URL":"https:\/\/doi.org\/10.1016\/j.freeradbiomed.2004.11.033","relation":{},"ISSN":["0891-5849"],"issn-type":[{"value":"0891-5849","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxidant stress but not thromboxane decreases with epoprostenol therapy","name":"articletitle","label":"Article Title"},{"value":"Free Radical Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.freeradbiomed.2004.11.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}